BioCentury
ARTICLE | Company News

uniQure paring down gene therapy portfolio

November 15, 2016 11:50 PM UTC

Gene therapy company uniQure N.V. (NASDAQ:QURE) said it will reduce headcount by 20-25%, eliminating 50-60 positions by YE17, in order to focus on key pipeline projects.

The company expects the job cuts will save EUR 5-6 million ($5.4-$6.4 million) annually, while reprioritizing the pipeline will reduce expenses by EUR 11-15 million ($11.8-$16.1 million) over two years...